Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials

• Richard F. Schlenk,
• Jürgen Krauter,
• Emmanuel Raffoux,
• Karl-Anton Kreuzer,
• Markus Schaich,
• Lucien Noens,
• Thomas Pabst,
• Madhuri Vusirikala,
• Didier Bouscary,
• Andrew Spencer,
• Anna Candoni,
• Jorge Sierra Gil,
• Noah Berkowitz,
• Hans-Jochen Weber,
• Oliver Ottmann

Affiliations

Richard F. Schlenk

NCT Trial Center, National Center for Tumor Diseases Heidelberg, Germany;University Hospital Ulm, Department of Internal Medicine III, Germany

Jürgen Krauter

Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany

Emmanuel Raffoux

Hôpital Saint-Louis – Service d’Hematologie Adulte, Paris, France

Karl-Anton Kreuzer

Department of Internal Medicine I, University of Cologne, Germany

Markus Schaich

University of Dresden, Department of Internal Medicine I, Germany

Lucien Noens

Universitair Ziekenhuis, Gent, Belgium

Thomas Pabst

Inselspital, Bern, Switzerland

Madhuri Vusirikala

University of Texas Southwestern Medical Center, Dallas, TX, USA

Didier Bouscary

Hôpital Cochin, Paris, France

Andrew Spencer

The Alfred Hospital, Melbourne, VIC, Australia

Anna Candoni

Azienda Ospedaliero-Universitaria “Santa Maria della Misericordia” di Udine, Italy

Jorge Sierra Gil

Hospital de la Santa Creu i Sant Pau, IIB Sant Pau and Jose Carreras Research Institutes, Barcelona, Spain

Noah Berkowitz

Novartis Pharmaceutical Corporation, East Hanover, NJ, USA;

Hans-Jochen Weber

Novartis Pharma AG, Basel, Switzerland

Oliver Ottmann

University of Frankfurt, Department of Internal Medicine II, Germany